Thanks to the zebrafish, there is new hope for people with melanoma, an aggressive skin cancer that is responsible for approximately 8,700 deaths each year in the United States.
In a study that was published in the March 24th issue of the journal Nature, and featured on the cover, researchers identified SETDB1 as a new gene that promotes the growth of melanoma and may play a role in up to 70 percent of malignant melanomas.
"We hope our discovery will ultimately lead to better therapeutic strategies for patients with melanoma," says study co-first author Dr. Yariv J. Houvras, assistant professor of medicine in the Departments of Surgery, Medicine, and Cell and Developmental Biology at Weill Cornell Medical College.
Although melanoma accounts for less than 5 percent of skin cancer cases, it causes a large majority of skin cancer deaths. The American Cancer Society estimates that about 68,000 were diagnosed in the United States last year -- 39,000 in men and 29,000 in women. The incidence of melanoma continues to increase at a rate faster than that of the seven most common cancers; according to the National Cancer Institute, between 1992 and 2004 the melanoma incidence increased 45 percent.
The report in Nature originated in the laboratory of Dr. Leonard Zon, director of the Stem Cell Program at Children's Hospital Boston, where Dr. Houvras worked prior to joining Weill Cornell earlier this year. Dr. Houvras and colleagues created "MiniCoopR," a transposon-based vector to deliver candidate human test genes into a specially engineered strain of zebrafish that harbors a mutated BRAF gene. The researchers screened more than 3,000 zebrafish and found one gene that dramatically accelerated melanoma formation: SETDB1, which encodes a histone methyltransferase enzyme. Fish melanomas with elevated levels of SETDB1 are highly invasive and have a set of deregulated genes that are present in human tumors with high levels of SETDB1.
The discovery that SETDB1 accelerates melanoma formation in zebrafish is important because SETDB1 appears to be frequently overexpressed in human melanomas. "SETDB1 is an enzyme, so it may be a good drug target," explains Dr. Houvras. In a second report from Dr. Zon's lab led by first author Dr. Richard White, researchers found that the combination of leflunomide, a drug used to treat arthritis, and a BRAF inhibitor in clinical development was effective in blocking the formation of stem cells in zebrafish that give rise to melanoma.
Dr. Houvras, who joined the faculty of Weill Cornell in January 2011, is a physician-scientist with a focus on cancer genetics. He received his M.D. and Ph.D. degrees from the Mount Sinai School of Medicine in New York City. He received his residency and fellowship training in internal medicine and hematology-oncology at the Massachusetts General Hospital and the Dana-Farber Cancer Institute, both in Boston. He was an instructor in medicine at Harvard Medical School and an assistant attending physician at Massachusetts General Hospital in hematology-oncology. Dr. Houvras has co-authored articles in Nature and the Journal of Biological Chemistry. His honors include a Young Investigator Award from the American Society of Clinical Oncology. Dr. Houvras is the recipient of a mentored physician-scientist training award from the National Institutes of Health.
Dr. Houvras has set up a laboratory at Weill Cornell to expand on the research in zebrafish on SETDB1 and cancer. "People are surprised when I tell them I use zebrafish to do cancer research. It is still amazing to me that the same genes that cause cancer in humans also cause cancer in fish. The zebrafish is an amazing organism because we can do complex genetic studies, and the fish has many of the same organs and tissues that we have," Dr. Houvras says.
He explains that the zebrafish is becoming a popular method for investigating malignancies, including melanoma, leukemia and sarcoma. "The melanoma model allowed us to integrate data from human genomic studies with the zebrafish. This made it possible to create thousands of transgenic animals and look for animals with more aggressive disease," Dr. Houvras says. "The zebrafish is an emerging organism in cancer biology. It has been an important organism for developmental biology and now we want to demonstrate that it has a unique set of attributes that we can use to discover new genes and treatments for patients with cancer."
Research with zebrafish has a practical side as well. The small, translucent embryos help make some processes, such as angiogenesis or genomic instability, more transparent. "For the melanoma studies, we designed and executed a study with more than 3,000 adult animals. It would have been very hard to do this kind of research with mice. I'm very excited about finding the right niche for zebrafish in cancer research. There are certain questions in cancer research that zebrafish are perfectly suited toward addressing. There is a great environment at Weill Cornell in the Departments of Surgery and Medicine for cancer research, and I am grateful that they provided me with a lab and a zebrafish facility to continue my research," Dr. Houvras says.
Besides Dr. Houvras, contributing authors to the paper included Craig J. Ceol, Caitlin Bourque, Christopher J. Burke, Laura Turner, Audrey Uong and Leonard Zon of Children's Hospital Boston, Howard Hughes Medical Institute, Harvard Stem Cell Institute, Boston, Mass.; Judit Jane-Valbuena, William M. Lin, Laura A. Johnson, Rameen Beroukhim, Craig H. Mermel and Levi A. Garraway of Departments of Medical Oncology, Cancer Biology, and Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Harvard Medical School and the Broad Institute of Harvard and Massachusetts Institute of Technology; Steve Bilodeau, David A. Orlando and Richard A. Young of the Whitehead Institute for Biomedical Research, Cambridge, Mass.; Valentine Battisti, Lauriane Fritsch and Slimane Ait-Si-Ali of Université Paris-Diderot (UMR 7216 Epigénétique et Destin Cellulaire), France; Travis J. Hollmann and Massimo Loda of the Center for Molecular Oncologic Pathology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass.; and Fabrizio Ferre, Sapienza University of Rome.
Weill Cornell Medical College
Weill Cornell Medical College, Cornell University's medical school located in New York City, is committed to excellence in research, teaching, patient care and the advancement of the art and science of medicine, locally, nationally and globally. Physicians and scientists of Weill Cornell Medical College are engaged in cutting-edge research from bench to bedside, aimed at unlocking mysteries of the human body in health and sickness and toward developing new treatments and prevention strategies. In its commitment to global health and education, Weill Cornell has a strong presence in places such as Qatar, Tanzania, Haiti, Brazil, Austria and Turkey. Through the historic Weill Cornell Medical College in Qatar, the Medical College is the first in the U.S. to offer its M.D. degree overseas. Weill Cornell is the birthplace of many medical advances -- including the development of the Pap test for cervical cancer, the synthesis of penicillin, the first successful embryo-biopsy pregnancy and birth in the U.S., the first clinical trial of gene therapy for Parkinson's disease, and most recently, the world's first successful use of deep brain stimulation to treat a minimally conscious brain-injured patient. Weill Cornell Medical College is affiliated with NewYork-Presbyterian Hospital, where its faculty provides comprehensive patient care at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. The Medical College is also affiliated with the Methodist Hospital in Houston, making Weill Cornell one of only two medical colleges in the country affiliated with two U.S.News & World Report Honor Roll hospitals. For more information, visit weill.cornell.edu.
Andrew Klein | EurekAlert!
What happens in the cell nucleus after fertilization
06.12.2016 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt
Researchers uncover protein-based “cancer signature”
05.12.2016 | Universität Basel
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
06.12.2016 | Power and Electrical Engineering
06.12.2016 | Earth Sciences
06.12.2016 | Physics and Astronomy